In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 61 for your search:

Drug:  pegfilgrastim
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase III Study of Neoadjuvant and Adjuvant Cisplatin-Based Chemotherapy and/or Surgical Resection in Young Patients With Stage I-IV Adrenocortical Tumor

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 22 at diagnosis
Sponsor: NCI
Protocol IDs: COG-ARAR0332, ARAR0332, NCT00304070

Phase III Randomized Pilot Study of Adjuvant Chemotherapy Comprising Doxorubicin Hydrochloride or Epirubicin Hydrochloride and Cyclophosphamide in Older Women With Invasive Breast Carcinoma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 70 and over
Sponsor: Other
Protocol IDs: UKM-CCH-ACTION, ICR-CTSU/2006/10004-ACTION, EU-20751, EUDRACT-2005-005721, ISRCTN41708421, BIG-205, BIG 2-05, NCT00516425

Phase III Randomized Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging in Patients With Newly Diagnosed Stage II-IV Hodgkin Lymphoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRUK-2007-006064-30, 2007-006064-30, CRUK-07/146, NCT00678327

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20080259, NCT00911170

Phase III Randomized Study of Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0250, GOG-0250, NCT01012297

Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: OSHO#069, NCT01497002

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LA-EP06-302, NCT01516736

Phase III Randomized Study of Adjuvant Chemotherapy Comprising Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride Versus Observation in Patients With Uterus-Limited, High-Grade Uterine Leiomyosarcoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0277, GOG-0277, NCT01533207

A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: HHPG-19K -III-02, NCT01560195

10.

A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: HHPG-19K -III-01, NCT01611051

11.

Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: DA3031_NP_III, NCT01674855

12.

Rituximab&Methotrexate Chemotherapy w/BBBD & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-1012, 3R01CA137488, 1012, SOL-05025-L, OHSU-SOL-05025-L, NCT00293475

13.

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000570266, MSKCC-05077, 05-077, NCT00546377

14.

Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 to 60
Sponsor: Other
Protocol IDs: CDR0000572096, USCTU-UR1002-GEM-TIP, EU-20769, EUDRACT-2004-004804-19, UR1002-Gem-TIP, NCT00551122

15.

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000594812, P30CA015083, MC078E, RV-NHL-PI-0325, 07-007992, NCI-2009-01196, MAYO-MC078E, CELGENE-RV-NHL-PI-0325, NCT00670358

16.

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-2188, 2188, SOL-06015, OHSU-SOL-06015, NCT00397501

17.

Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 30
Sponsor: Other
Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398

18.

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0065, NCT01169636

19.

Phase I/II Study of Dose-Dense Pegfilgrastim and Sargramostim as Support for Dose-Dense Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, Prednisone, and Rituximab (R-CHOP) Front-Line Therapy in Patients With Previously Untreated Aggressive Stage I-IV Non-Hodgkin Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CCAM-05-02, CCAM 05-02, NCT01297478

20.

Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2010-0991, NCT01371630

21.

Phase II Study of Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-2903, NCT00074282, E2903

22.

Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma

Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: SD01-20010120, NCT00050674

23.

Chemotherapy Administered Every 2 Weeks with or without Pegfilgrastim (Neulasta) in Subjects with Advanced Colon Cancer

Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20020715, UCLA-0412010-01, AMGEN-20020715, NCT00094809

24.

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: CDR0000454505, DSHNHL-2004-1, EU-20536, DSHNHL-CHOP-R-ESC, EUDRACT-2005-00529-68, NCT00290667

25.

Pegfilgrastim Vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-Lymphoma